TYK Medicines-B (02410) releases annual performance, R&D costs amount to approximately 2.44 billion yuan, a year-on-year increase of 3.7%.

TYK MEDICINES-B(02410) announced its annual performance for the year ending on December 31, 2025, with research and development costs of approximately 244 million yuan, an increase of 3.7% year-on-year; other income and gains of 37.609 million yuan, an increase of 23.14% year-on-year. During the reporting period, other income and gains mainly included government subsidies related to income, government subsidies related to interest-free financing, and gains from the sale of a subsidiary. As a company focusing on the development of small molecule targeted therapies for cancer treatment, the company has established a pipeline consisting of 10 candidate drugs. The company has gradually supplemented the commercialization team on the basis of the original organizational structure, exploring market potential, continuously exploring the sales potential of products in depth, enriching brand promotion, and enhancing the visibility of the enterprise brand in the industry through various forms such as participating in academic conferences, industry cooperation, platform cooperation, etc.